GSK Spinout BHV Seeks Funds For Phase II Diabetes Drug
By Trista Morrison
Friday, January 27, 2012
Developing diabetes drugs is no easy task. It's even harder if a start-up has to convince venture capitalists it can clear the FDA's high diabetes hurdles. And it's harder still if the FDA has just rejected a drug with the same mechanism of action.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.